Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells

(2009) W. Fiskus et al.   BLOOD

Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer

(2009) Meng Li et al.   BMC Medical Genomics

Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo

(2009) N Steele et al.   BRITISH JOURNAL OF CANCER

Histone deacetylase inhibitors as anti-neoplastic agents

(2009) Nicolas Batty et al.   CANCER LETTERS

EZH2 Is Essential for Glioblastoma Cancer Stem Cell Maintenance

(2009) M.-L. Suva et al.   CANCER RESEARCH

Cancer-Specific High-Throughput Annotation of Somatic Mutations: Computational Prediction of Driver Missense Mutations

(2009) H. Carter et al.   CANCER RESEARCH

Decitabine Effect on Tumor Global DNA Methylation and Other Parameters in a Phase I Trial in Refractory Solid Tumors and Lymphomas

(2009) D. J. Stewart et al.   CLINICAL CANCER RESEARCH

Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib

(2009) Henk J. Broxterman et al.   DRUG RESISTANCE UPDATES

The promises and pitfalls of epigenetic therapies in solid tumours

(2009) Janet S. Graham et al.   EUROPEAN JOURNAL OF CANCER

Epigenetic therapies for chemoresensitization of epithelial ovarian cancer

(2009) Daniela E. Matei et al.   GYNECOLOGIC ONCOLOGY

Histone deacetylase inhibitors: Potential in cancer therapy

(2009) P.A. Marks et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Gastrosplenic Fistula From Hodgkin's Lymphoma

(2009) Carolyn D. Seib et al.   JOURNAL OF CLINICAL ONCOLOGY

Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer

(2009) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation

(2009) T. B. Miranda et al.   MOLECULAR CANCER THERAPEUTICS

Methylation Linear Discriminant Analysis (MLDA) for identifying differentially methylated CpG islands

(2008) Wei Dai et al.   BMC BIOINFORMATICS

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

(2008) Joshua Z Press et al.   BMC CANCER

Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors

(2008) S. Zhang et al.   CANCER RESEARCH

MicroRNA Microarray Identifies Let-7i as a Novel Biomarker and Therapeutic Target in Human Epithelial Ovarian Cancer

(2008) N. Yang et al.   CANCER RESEARCH

Resistance to therapy caused by intragenic deletion in BRCA2

(2008) Stacey L. Edwards et al.   NATURE

DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes

(2008) Elizabeth A. Griffiths et al.   SEMINARS IN HEMATOLOGY

Gene-expression profiling in epithelial ovarian cancer

(2008) Panagiotis A Konstantinopoulos et al.   Nature clinical practice. Oncology

Expression of CD133-1 and CD133-2 in ovarian cancer

(2007) G. FERRANDINA et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER